Элиглустат (GZ385660)
Проводит Джензайм
Страница компанииОткрытое многоцентровое международное исследование 3b фазы по оценке влияния лечения элиглустатом на кости скелета у взрослых пациентов, которые успешно завершили участие в исследованиях 2 или 3 фазы
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/418/2015-08-04/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 26 чел. в стране «Россия».
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (12.2021) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 4 · невключение: 13
Критерии включения
- The participant must have successfully completed the Phase 2 (GZGD00304) or a Phase 3 study (GZGD02507, GZGD02607 or GZGD03109). Successful completion was defined as participants enrolled in one of the above mentioned studies who received eliglustat through the end of the study and completed the end-of-study visit without having discontinued or been withdrawn prematurely.
- The participant was willing and able to provide signed informed consent prior to any protocol-required procedures being performed.
- Female participants of childbearing potential must have had a documented negative pregnancy test prior to enrollment and while they were receiving eliglustat treatment.
- Female participants of childbearing potential must have been willing to practice true abstinence in line with their preferred and usual lifestyle, or used a medically accepted form of contraception (either a barrier method, such as condom or diaphragm + spermicide, or a non-barrier method such as oral, injected, or implanted hormonal methods, or an intra-uterine device or system) while receiving eliglustat.
Критерии невключения
- The participant was unwilling to comply with the requirements of the protocol.
- The participant had received an investigational product (other than eliglustat) within 30 days prior to enrollment.
- The participant had received miglustat within the 6 months prior to enrollment.
- The participant had documented prior esophageal varices or liver infarction or current liver enzymes (alanine transaminase, aspartate aminotransferase) or total bilirubin greater than (>)2 times the upper limit of normal, unless the participant had a diagnosis of Gilbert Syndrome.
- The participant had any clinically significant disease, other than Gaucher disease, including cardiovascular, renal, hepatic, gastrointestinal, pulmonary, neurologic, endocrine, metabolic (eg, hypokalemia, hypomagnesemia), or psychiatric disease, other medical conditions, or serious intercurrent illnesses that might preclude participation in the study.
- The participant was known to have any of the following: cardiac disease (congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT syndrome, or current treatment with Class IA or Class III antiarrhythmic medicinal products.
- The participant had tested positive for the human immunodeficiency virus antibody, hepatitis C antibody, or hepatitis B surface antigen.
- The participant had a history of cancer within 6 months of enrolment, with the exception of basal cell carcinoma.
- Participant was a CYP2D6 IM, EM or URM and was taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor.
- Participant was a CYP2D6 PM having taken a strong CYP3A inhibitor within 2 weeks prior to enrolment.
- If a female participant of childbearing potential had a positive pregnancy test (blood β-human chorionic gonadotropin \[β-HCG\]) or was breastfeeding prior to first dosing of eliglustat in this study, the participant could not enroll in the study at that time, but might have been rescreened after the end of the pregnancy, and/or when she was no longer breast feeding, provided rescreening took place before the end of the enrollment period.
- Women of childbearing potential who were unwilling or unable to be tested for pregnancy.
- The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Источник: ClinicalTrials.gov, NCT02536755 · запись обновлена в реестре 15 июля 2022.
Дизайн и результаты
Что измеряют — первичные конечные точки (10), вторичных — 9
- Number of Participants With Mobility Status Assessments at Study Baseline, Weeks 52, 104, 156 and 208 — Study Baseline, Weeks 52, 104, 156 and 208
- Number of Participants With Bone Pain Levels During the Past 4 Weeks at Study Baseline, Weeks 52, 104, 156 and 208 — Study Baseline, Weeks 52, 104, 156 and 208
- Number of Participants With Bone Crisis at Study Baseline, Weeks 52, 104, 156 and 208 — Study Baseline, Weeks 52, 104, 156 and 208
- Change From Current Study Baseline in Total Bone Marrow Burden (BMB) Scores at Weeks 52, 104, 156 and 208 — Study Baseline, Weeks 52, 104, 156 and 208
- Change From Eliglustat Baseline in Total Bone Marrow Burden (BMB) Scores at Weeks 52, 104, 156 and 208 — Eliglustat Baseline, Weeks 52, 104, 156 and 208 of the current study
- Change From Current Study Baseline in Total Spine and Femur Bone Mineral Density (BMD) at Weeks 52, 104, 156 and 208 — Study Baseline, Weeks 52, 104, 156 and 208
- Change From Eliglustat Baseline in Total Spine and Femur Bone Mineral Density (BMD) at Weeks 52, 104, 156 and 208 — Eliglustat Baseline, Weeks 52, 104, 156 and 208 of the current study
- Change From Current Study Baseline in Spine and Femur Total T-Scores for BMD at Weeks 52, 104, 156 and 208 — Study Baseline, Weeks 52, 104, 156 and 208
- Change From Eliglustat Baseline in Spine and Femur Total T-Scores for BMD at Weeks 52, 104, 156 and 208 — Eliglustat Baseline, Weeks 52, 104, 156 and 208 of the current study
- Change From Current Study Baseline in Spine and Femur Total Z-Scores for BMD at Weeks 52, 104, 156 and 208 — Study Baseline, Weeks 52, 104, 156 and 208
Цель исследования
Primary Objective:
Evaluate long term skeletal response to eliglustat in adult participants who successfully completed one of the Phase 2 or Phase 3 eliglustat studies.
Secondary Objective:
Evaluate the safety of eliglustat (by serious adverse event continuous monitoring), the quality of life (Short Form-36 Health Survey \[SF-36\]) and biomarkers of Gaucher disease type 1 (GD1) (chitotriosidase, plasma glucosylceramide \[GL-1\] and lyso glucosylceramide \[lyso-GL-1\]) in adult participants who successfully completed one of the Phase 2 or Phase 3 studies.
Области и заболевания
Где проходит
1 центр в 1 городеОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 418 от 04.08.2015 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик, центры
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02536755 Официальный реестр (США) · загружено 9 ноября 2026Цель
-
clinmarket · № 3596 Каталог исследований · загружено 1 октября 2026Статус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.